SAN DIEGO, June 6, 2011 /PRNewswire/ -- Thirty-six million Americans suffer from migraines, leading to more than $20 billion in medical expenses and costs related to lost productivity each year(1). In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient's "treatment toolbox" to address specific types of migraine episodes. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/zogenix/50344/ This multi-therapy treatment strategy is endorsed by headache specialists and is supported by the results of a Phase 4 clinical study of the Company's fast-acting needle-free subcutaneous migraine treatment, SUMAVEL DosePro, which were presented at the annual meeting of the American Headache Society in Washington, D.C. The study demonstrated increased patient satisfaction, confidence and preference for SUMAVEL DosePro in the treatment of migraine attacks. Roger K. Cady, MD, associate executive chairman of the National Headache Foundation board of directors and founder of the Headache Care Center in Springfield, MO, said, "Migraines are a serious medical condition that can severely impair a patient's ability to function in day-to-day activities. They are difficult to treat because there is a broad spectrum of migraines with significant variability in intensity, nausea, associated vomiting and speed of onset. Clinical experience suggests that the key to winning the battle is a multi-therapy approach that includes a fast-acting, convenient and easy-to use option for the more aggressive migraine attacks." Oral triptans are a commonly prescribed class of migraine medications, however, more than 50% of migraine sufferers using oral medications have indicated they are dissatisfied with their current migraine therapy(2).